Bederra marks first medical buy with Diagnos' imaging tech
This article was originally published in Clinica
Equipment leasing company Bederra has acquired diagnostic imaging company Diagnos in exchange for 15 million shares. The deal, which saw Diagnos become a wholly-owned subsidiary of Bederra on December 27 2007, enables the Texas, Houston-based acquirer to offer its customers PET technology designed to detect cancer, Alzheimer's disease, dementia and heart disease. Diagnos' technology currently only has an installed base of 18 units all within the Houston area. The company will hope the Bederra deal opens up new sales routes to more states for the technology. The PET technology is accepted by Medicare and all private insurance carriers. President of Bederra Graham Williams said this acquisition marked the first of many acquisitions in the medical sector that the company had planned in the coming years. According to Bederra, the equipment leasing market generates revenues of around $200bn every year.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.